{
    "root": "34f3d0ae-813c-3d96-e063-6294a90adaf4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Olanzapine",
    "value": "20250512",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "OLANZAPINE",
            "code": "N7U69T4SZR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7735"
        }
    ],
    "indications": {
        "text": "olanzapine atypical antipsychotic indicated : oral formulation : \u00b7 treatment schizophrenia . ( 1.1 ) \u00b7 adults : efficacy established three trials patients schizophrenia : two 6-week trials one maintenance trial . ( 14.1 ) \u00b7 adolescents ( ages 13-17 ) : efficacy established one 6-week trial patients schizophrenia ( 14.1 ) . increased potential ( adolescents compared adults ) weight gain dyslipidemia may lead clinicians consider prescribing drugs first adolescents . ( 1.1 ) \u00b7 acute treatment manic mixed episodes associated bipolar disorder maintenance treatment bipolar disorder . ( 1.2 ) \u00b7 adults : efficacy established three trials patients manic mixed episodes bipolar disorder : two 3- 4-week trials one maintenance trial . ( 14.2 ) \u00b7 adolescents ( ages 13-17 ) : efficacy established one 3-week trial patients manic mixed episodes associated bipolar disorder ( 14.2 ) . increased potential ( adolescents compared adults ) weight gain dyslipidemia may lead clinicians consider prescribing drugs first adolescents . ( 1.2 ) \u00b7 medication therapy pediatric patients schizophrenia bipolar disorder undertaken thorough diagnostic evaluation careful consideration potential risks . ( 1.3 ) \u00b7 adjunct valproate lithium treatment manic mixed episodes associated bipolar disorder . ( 1.2 ) \u00b7 efficacy established two 6-week trials adults ( 14.2 ) . maintenance efficacy systematically evaluated . olanzapine fluoxetine combination : treatment depressive episodes associated bipolar disorder . ( 1.5 ) \u2022 efficacy established symbyax ( olanzapine fluoxetine combination ) ; refer product label symbyax . treatment treatment resistant depression . ( 1.6 ) \u2022 efficacy established symbyax ( olanzapine fluoxetine combination ) adults ; refer product label symbyax",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "dyslipidemia (DOID:3146)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3146"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "depression (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "schizophrenia adults ( 2.1 ) oral : start 5\u201110 mg daily ; target : 10 mg/day within several days schizophrenia adolescents ( 2.1 ) oral : start 2.5\u20115 mg daily ; target : 10 mg/day bipolar disorder ( manic mixed episodes ) adults ( 2.2 ) oral : start 10 15 mg daily bipolar disorder ( manic mixed episodes ) adolescents ( 2.2 ) oral : start 2.5-5 mg daily ; target : 10 mg/day bipolar disorder ( manic mixed episodes ) lithium valproate adults ( 2.2 ) oral : start 10 mg daily depressive episodes associated bipolar disorder adults ( 2.5 ) oral combination fluoxetine : start 5 mg oral olanzapine 20 mg fluoxetine daily depressive episodes associated bipolar disorder children adolescents ( 2.5 ) oral combination fluoxetine : start 2.5 mg oral olanzapine 20 mg fluoxetine daily treatment resistant depression adults ( 2.6 ) oral combination fluoxetine : start 5 mg oral olanzapine 20 mg fluoxetine daily \u2022 lower starting dose recommended debilitated pharmacodynamically sensitive patients patients predisposition hypotensive , potential slowed metabolism . ( 2.1 ) \u2022 olanzapine may given without regard meals . ( 2.1 ) olanzapine fluoxetine combination : \u2022 adjustments , indicated , made individual components according efficacy tolerability . ( 2.5 , 2.6 ) \u2022 olanzapine monotherapy indicated treatment depressive episodes associated bipolar disorder treatment resistant depression . ( 2.5 , 2.6 ) \u2022 safety co-administration doses 18 mg olanzapine 75 mg fluoxetine evaluated adults . ( 2.5 , 2.6 ) \u2022 safety co-administration doses 12 mg olanzapine 50 mg fluoxetine evaluated children adolescents ages 10 17 . ( 2.5 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "depression (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "16.1 supplied olanzapine tablets , usp 2.5 mg , white white coloured , round shaped , biconvex , film coated tablets debossed \u2018 cl \u2019 one side , \u2018 39 \u2019 side ndc 71335-1760-1 30 tablets bottle ndc 71335-1760-2 15 tablets bottle ndc 71335-1760-3 28 tablets bottle ndc 71335-1760-4 60 tablets bottle 16.2 storage handling store olanzapine tablets , usp controlled room temperature , 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp ] . usp defines controlled room temperature temperature maintained thermostatically encompasses usual customary working environment 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; results mean kinetic temperature calculated 25\u00b0c ; allows excursions 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) experienced pharmacies , hospitals , warehouses . protect olanzapine tablets , usp light moisture . repackaged/relabeled : bryant ranch prepack , inc. burbank , ca 91504",
    "adverseReactions": "\u2022 none olanzapine tablets monotherapy . \u2022 using olanzapine fluoxetine combination , also refer section package insert symbyax . \u2022 information lithium valproate , refer section package inserts products .",
    "indications_original": "Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: \u00b7\u00a0\u00a0 Treatment of schizophrenia. ( 1.1 ) \u00b7\u00a0\u00a0 Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial.\u00a0( 14.1 ) \u00b7\u00a0\u00a0 Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and\u00a0dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) \u00b7\u00a0\u00a0 Acute treatment of manic or mixed episodes associated with bipolar\u00a0I disorder and maintenance treatment of bipolar\u00a0I disorder. ( 1.2 ) \u00b7\u00a0\u00a0 Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar\u00a0I disorder: two 3- to 4-week trials and one maintenance trial. ( 14.2 ) \u00b7\u00a0\u00a0 Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14.2 ). The increased potential (in adolescents compared with adults) for weight gain and\u00a0dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.2 ) \u00b7\u00a0\u00a0 Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. ( 1.3 ) \u00b7\u00a0\u00a0 Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar\u00a0I disorder. ( 1.2 ) \u00b7\u00a0\u00a0 Efficacy was established in two 6-week clinical trials in adults ( 14.2 ). Maintenance efficacy has not been systematically evaluated. As Olanzapine and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bipolar I disorder. ( 1.5 ) \u2022\u00a0Efficacy was established with Symbyax (olanzapine and fluoxetine in combination); refer to the product label for Symbyax. Treatment of treatment resistant depression. ( 1.6 ) \u2022\u00a0Efficacy was established with Symbyax (olanzapine and fluoxetine in combination) in adults; refer to the product label for Symbyax",
    "contraindications_original": "Schizophrenia in adults ( 2.1 ) Oral: Start at 5\u201110\u00a0mg once daily; Target: 10\u00a0mg/day within several days Schizophrenia in adolescents ( 2.1 ) Oral: Start at 2.5\u20115\u00a0mg once daily; Target: 10\u00a0mg/day Bipolar I Disorder (manic or mixed episodes) in adults ( 2.2 ) Oral: Start at 10 or 15\u00a0mg once daily Bipolar I Disorder (manic or mixed episodes) in adolescents ( 2.2 ) Oral:\u00a0 Start at 2.5-5 mg once daily; Target: 10 mg/day Bipolar I Disorder (manic or mixed episodes) with lithium or valproate in adults ( 2.2 ) Oral: Start at 10\u00a0mg once daily Depressive Episodes associated with Bipolar\u00a0I Disorder in adults ( 2.5 ) Oral in combination with fluoxetine: Start at 5\u00a0mg of oral olanzapine and 20\u00a0mg of fluoxetine once daily Depressive Episodes associated with Bipolar\u00a0I Disorder in children and adolescents ( 2.5 ) Oral in combination with fluoxetine: Start at 2.5\u00a0mg of oral olanzapine and 20\u00a0mg of fluoxetine once daily Treatment Resistant Depression in adults\u00a0( 2.6 ) Oral in combination with fluoxetine: Start at 5\u00a0mg of oral olanzapine and 20\u00a0mg of fluoxetine once daily \u2022\u00a0Lower starting dose recommended in debilitated or pharmacodynamically sensitive patients or patients with predisposition to hypotensive reactions, or with potential for slowed metabolism. ( 2.1 ) \u2022\u00a0Olanzapine may be given without regard to meals. ( 2.1 ) Olanzapine and Fluoxetine in Combination: \u2022\u00a0Dosage adjustments, if indicated, should be made with the individual components according to efficacy and tolerability. ( 2.5 , 2.6 ) \u2022\u00a0Olanzapine monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder or treatment resistant depression. ( 2.5 , 2.6 ) \u2022\u00a0Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults. ( 2.5 , 2.6 ) \u2022\u00a0Safety of co-administration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17. ( 2.5 )",
    "warningsAndPrecautions_original": "16.1 How Supplied\n  \nOlanzapine tablets, USP 2.5 mg, are white to off white coloured, round shaped, biconvex, film coated tablets debossed \u2018CL\u2019 on one side, and \u201839\u2019 on other side\n \n                  \n                     NDC 71335-1760-1 30 Tablets in a BOTTLE\n                     NDC 71335-1760-2 15 Tablets in a BOTTLE\n                     NDC 71335-1760-3 28 Tablets in a BOTTLE\n                     NDC 71335-1760-4 60 Tablets in a BOTTLE\n                  \n                  16.2 Storage and Handling\n  \nStore olanzapine tablets, USP at controlled room temperature, 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP]. The USP defines controlled room temperature as a temperature maintained thermostatically that encompasses the usual and customary working environment of 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); that results in a mean kinetic temperature calculated to be not more than 25\u00b0C; and that allows for excursions between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F) that are experienced in pharmacies, hospitals, and warehouses.\n \n                  Protect olanzapine tablets, USP from light and moisture.\n                  \n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions_original": "\u2022\u00a0None with olanzapine tablets monotherapy. \n    \u2022\u00a0When using olanzapine and fluoxetine in combination, also refer to the Contraindications section of the package insert for Symbyax. \n    \u2022\u00a0For specific information about the contraindications of lithium or valproate, refer to the Contraindications section of the package inserts for these other products.",
    "drug": [
        {
            "name": "Olanzapine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7735"
        }
    ]
}